Simplify Asset Management Inc. Boosts Stake in Eyepoint Pharmaceuticals, Inc. $EYPT

Simplify Asset Management Inc. raised its holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 314.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 375,264 shares of the company’s stock after purchasing an additional 284,824 shares during the quarter. Eyepoint Pharmaceuticals accounts for 0.1% of Simplify Asset Management Inc.’s holdings, making the stock its 28th largest holding. Simplify Asset Management Inc.’s holdings in Eyepoint Pharmaceuticals were worth $6,856,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EYPT. State of Alaska Department of Revenue purchased a new stake in Eyepoint Pharmaceuticals in the third quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. raised its position in Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the period. Russell Investments Group Ltd. purchased a new stake in Eyepoint Pharmaceuticals in the third quarter valued at $76,000. Tower Research Capital LLC TRC raised its position in Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares during the period. Finally, Raymond James Financial Inc. raised its position in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $12.93 on Monday. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $19.11. The company has a 50 day moving average price of $13.46 and a 200 day moving average price of $14.68. The stock has a market capitalization of $1.08 billion, a P/E ratio of -3.69 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. On average, research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.16 EPS for the current fiscal year.

Insider Buying and Selling at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on EYPT. Chardan Capital lifted their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright lifted their target price on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, April 21st. Royal Bank Of Canada cut their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Citigroup raised their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.80.

Eyepoint Pharmaceuticals Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.